In mouse HCC models, the combination of ICIs (anti-CTLA-4 and anti-PD-1) with histone deacetylase inhibitor Belinostat induced early upregulation of PD-L1 on tumor antigen presenting cells and late expression of PD-1 on tumor infiltrating effector T cells. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.